Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus MPI DMSA KIDNEY REAGENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus MPI DMSA KIDNEY REAGENT.
CERETEC vs MPI DMSA KIDNEY REAGENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical